Dopamine agonists and antagonists

Figure 7.6 Chemical structures of some dopamine agonists and antagonists...

Bannon, M.J. Elliot, PJ. and Bunny, E.B. Striatal tachykinin biosynthesis Regulation of mRNA and peptide levels by dopamine agonists and antagonists. Mol Brain Res 3 31-37, 1987. 

Ellinwood, E.H., Jr., and Kilbey, M.M. Alteration in motor frequencies with dopamine agonists and antagonists. Psychopharmacol Bull 15 49-50, 1979. 

All the pharmacological and behavioural effects elicited by dopamine agonists and antagonists in the brain can only be explained if such an interaction occurs at the level of the dopamine receptor (D2 receptor site) the site still remains in search of a function. Bovine parathyroid cells were reported to possess dopamine sites which should be involved in the control of parathormone secretion. However, the very poor pharmacological characterization and the lack of in vivo evidence do not allow to assess the dopaminergic nature of this hormone secretion. Dopamine-sensitive adenylate cyclase is thus not a receptor directly implicated in the dopaminergic neurotransmission it is an enzyme which could have an important role in the control of long term metabolic effects such as the synthesis of neuronal constituents. 

Dopamine Agonists and Antagonists in Duodenal Ulcer Disease... 

Keefe KA, Gerfen CR (1995) D1-D2 dopamine receptor synergy in striatum effects of intrastriatal infusions of dopamine agonists and antagonists on immediate early gene expression. Neuroscience 66 903-913. 

Beninger RJ, Mazurski EJ, Hoffman DC (1991) Receptor subtype-specific dopamine agonists and antagonists and unconditioned behavior. Pol J Pharmacol Pharm 45 507-528. 

Samson HH, Hodge CW, Tolliver GA, Haraguchi M (1993) Effect of dopamine agonists and antagonists on ethanol reinforced behavior the involvement ofthe nucleus accumbens. Brain Res Bull 30 133-141. 

For CNS aspects of dopamine, agonists and antagonists see Neuroleptics, Parkinsonism. 

Heikkila, R. E., Cabbat, F. S., and Manzino, L., Differential inhibitory effects of ascorbic acid on the binding of dopamine agonists and antagonists to neostri-atal membrane preparations Correlations with behavioral effects, Res. Com-mun. Chem. Pathol. Pharmacol., 34[3], 409, 1981. 

Kayaalp, S. O., and Neff, N. H., 1980, Differentiation by ascorbic acid of dopamine agonist and antagonist binding sites in striatum. Life Sci. 26 1837-1841. 

Szabo S, Neumeyer JL (1983) Dopamine agonists and antagonists in duodenal ulcer disease. 

---